Every round on record, with the sources behind each and the investors on them.
A molecular information company
arboretum.bioCambridge, MABiotech
8 sources
Source 1 metadata says 2026-10-05, but its release dateline and Business Wire fix the announcement to 2026-10-06.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $30M | 2026-10-05 | .406 Ventures, Amgen Ventures, F-Prime Capital, GV (Google Ventures), Hims & Hers | No recent discussion |
8 sources [ VERIFIED · CORRECTED ] read against 4 of 8 sources
Source 1 metadata says 2026-10-05, but its release dateline and Business Wire fix the announcement to 2026-10-06. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]8 pages read: arboretum.bio, businesswire.com, axios.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 4 of 8 sources·[ AGENT ]company research by the Firecrawl agent | ||||
Arboretum LifeSciences builds AI-enabled genetic-testing and molecular-data programs for healthcare systems and biopharma companies working to improve precision medicine for common diseases.
The company says precision medicine has advanced in cancer and rare disease but common-disease care still relies on one-size-fits-all trials that are large, costly, and prone to late-stage failure. Its $30 million Series A backs an AI-and-genetic-testing network for healthcare systems and biopharma intended to identify genetically defined patients, improve care, and make clinical trials more efficient.